Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Secondary Hemophagocytic Syndrome
NCT02400463Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by University of Michigan Rogel Cancer Center. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT02400463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400463.